| Literature DB >> 27272890 |
Yordanos M Tiruneh1, Omar Galárraga1, Becky Genberg1, Ira B Wilson1.
Abstract
BACKGROUND: Poor retention in HIV care challenges the success of antiretroviral therapy (ART). This study assessed how well patients stay in care and explored factors associated with retention in the context of an initial ART rollout in Sub-Saharan Africa.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27272890 PMCID: PMC4896473 DOI: 10.1371/journal.pone.0156619
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow chart of subject recruitment and follow-up.
Socio-demographic and Baseline Clinical Characteristics of Participants.
| Characteristic | N(%) |
|---|---|
| Age (median (IQR) = 34 (28–40)) | |
| 18–34 | 201 (52.2) |
| 35 and above | 184 (47.8) |
| Gender (female) | 248 (64.4) |
| Religion | |
| Orthodox Christian | 303 (78.7) |
| Protestant Christian | 33(9) |
| Muslim | 44 (11.4) |
| Others | 5 (1) |
| Marital Status | |
| Never Married | 105 (27.3) |
| Married | 154 (40) |
| Divorced/Separated | 54 (14) |
| Widow/Widower | 72 (18.7) |
| Education | |
| No formal education | 57 (14.8) |
| Primary | 124 (32.2) |
| Secondary | 137 (35.6) |
| Tertiary | 63 (16.4) |
| Employment status | |
| Employed | 121 (31.9) |
| Unemployed | 102 (26.9) |
| Unable to work/study due to illness | 156 (41.2) |
| Baseline CD4 count (mean = 124 cells/ μL) | |
| Under 100 cells/ μL | 160 (42) |
| 100–200 cells/ μL | 166 (43.6) |
| Above 200 cells/ μL | 55 (14.4) |
| WHO stage | |
| Stages I and II | 93 (24.7) |
| Stage III | 161 (42.8) |
| Stage IV | 122 (32.4) |
| Baseline Functional Status | |
| Working | 248 (66) |
| Ambulatory | 89 (23.7) |
| Bedridden | 39 (10.4) |
| ART regimen at initiation | |
| Nevirapine based regimen | 251 (65.5) |
| Efavirenz based regimen | 132 (34.5) |
| TB co-infection before ART | 37 (9.6) |
| TB co-infection while on ART | 11 (2.9) |
* Others include Catholics and non-believers.
Fig 2Kaplan-Meier LTFU Estimates by Baseline CD4 Cell Count of Participants, 2005–2011.
The event of interest is LTFU—missing appointments for more than three months after the last scheduled visit or administrative censoring. People who died or transferred out their care to other facilities were censored.
Univariate and Multivariate Cox Regression Analysis of Factors Associated with Lost-To-Follow-Up (LTFU)
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| Characteristics | HR (CI-95%) | P-value | HR (CI-95%) | P-value | |
| Age | |||||
| 18–34 | 1.33 (0.914–1.923) | 0.137 | 1.34 (0.871–2.077) | 0.181 | |
| 35 and above | 1 | 1 | |||
| Gender | |||||
| Male | 1.08 (0.740–1.578) | 0.688 | 1.1 (0.700–1.723) | 0.684 | |
| Female | 1 | 1 | |||
| Education | |||||
| Primary or no education | 1.47 (1.008–2.132) | 0.046 | 1.5 (1.003–2.238) | 0.048 | |
| Secondary or tertiary | 1 | 1 | |||
| Stigma concern | |||||
| No | 1.36 (0.937–1.969) | 0.106 | 1.23 (0.820–1.857) | 0.314 | |
| Yes | 1 | 1 | |||
| Baseline CD4 count | |||||
| Under 100 cells/ μL | 1.85 (1.212–2.831) | 0.004 | 1.62 (1.028–2.550) | 0.037 | |
| 100–200 cells/ μL | 1 | 1 | |||
| Above 200 cells/ μL | 2.39 (1.410–4.044) | 0.001 | 2.06 (1.146–3.698) | 0.016 | |
| WHO stage | |||||
| Stages I and II | 1 | 1 | |||
| Stage III | 1.46 (0.873–2.435) | 0.150 | 1.23 (0.721–2.105) | 0.445 | |
| Stage IV | 1.73 (1.020–2.934) | 0.042 | 1.17 (0.648–2.116) | 0.600 | |
| Baseline Functional Status | |||||
| Working | 1 | 1 | |||
| Ambulatory | 1.27 (0.810–2.000) | 0.296 | 1.20 (0.742–1.951) | 0.454 | |
| Bedridden | 2.92 (1.743–4.880) | 0.000 | 2.05 (1.105–3.804) | 0.023 | |
* P<0.05